continu progress
sale exceed our/street estim
days-adjust constant-curr basi sale grew cc day adjust
one bill day hip drove out-performance versu estim
knee line think days-adjust rosa initi
roll-out contribut versu estim better sg leverag off-set lower gross
margin lead slightli higher oper margin ep
us/street estimate higher sale reiter guidanc manag
highlight progress sever front quarter continu suppli stabil pivot
increas manufactur effici sever sale driver ahead includ strong
rosa knee demand persona revision/cementless knee new spine launch
invest special salesforc
recon market firm report hip/kne days-adjust growth jnj/
snn/syk/zbh market versu despit
tougher comp almost growth four compani
knee/hip price versu jnj/syk also
note orthoped price line slightli better sequenti
knee updat rosa placement contribut less half overal knee growth
accord manag assum sale custom pipelin
continu grow feedback remain solid manag also highlight
recent fda clearanc persona revis system on-going persona
cementless knee anoth build growth driver rosa cementless also
debt paydown net-debt/ebitda
firm balanc sheet busi stabil believ provid potenti tuck-in
 manag see pathway though wamgr exclud
commun fda continu work toward full remedi
north campu facil engag third parti mock audit
 highlight forecast slight gm improv hedg gain
one-tim benefit med-tech tax rebat expect gm declin slightli
hedg gain wane on-going shift focu cost effici
suppli triag bode well gm expans save flow cog
assum exit
estim sale rise almost cc
ep remain sale estim lower slightli
fx ep remain assum slight margin
expans led sg gm also driver use cash
repres upsid estim
year price histori
manufactur
distribut orthoped dental
trauma product relat surgic
analyst certif import disclosur see disclosur
underli sale growth improv full year sale growth
almost
free cash flow use paydown debt guidanc
sg leverag begin build signific impact yet
suppli chain effici work gross margin side
price-to-earnings share trade discount
large-cap peer mileston look forward
shift focu improv suppli cost reduct initi
continu build-out special salesforc new
product launch led robot knee spine system knee
on-going spine key launch includ
persona cementless full launch underway revis
persona cementless on-going revis knee launch
launch rosa knee spine
benefit salesforc build-out
quicker share recaptur improv suppli
faster acceler busi outsid large-joint ortho
use growth enhanc tuck-in
neg respons fda warn letter respons
slower expect hip/kne market growth
greater expect impact competitor rollout
price target driven blend discount cash flow compar pe analysi dcf use weight
averag cost capit wacc termin growth rate estim ebitda target impli
price-to-earnings multipl ep
risk price target includ wors expect price pressur key market declin procedur macro headwind
greater expect impact competitor rollout
includ expect one-tim gross margin benefit revers previou med-tech tax accrual bp estim posit impact
stock price compani mention report
